KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Hims & Hers Health (HIMS) EBITDA Margin (2020 - 2025)

Hims & Hers Health's EBITDA Margin history spans 6 years, with the latest figure at 3.56% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 174.0% year-over-year to 3.56%; the TTM value through Dec 2025 reached 5.58%, down 294.0%, while the annual FY2025 figure was 5.58%, 294.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 3.56% at Hims & Hers Health, up from 2.65% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 18.92% in Q3 2024 and bottomed at 98.38% in Q1 2021.
  • The 5-year median for EBITDA Margin is 3.4% (2023), against an average of 9.07%.
  • The largest annual shift saw EBITDA Margin plummeted -7817bps in 2021 before it surged 8215bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 36.89% in 2021, then soared by 83bps to 6.41% in 2022, then skyrocketed by 108bps to 0.51% in 2023, then surged by 941bps to 5.29% in 2024, then tumbled by -33bps to 3.56% in 2025.
  • Per Business Quant, the three most recent readings for HIMS's EBITDA Margin are 3.56% (Q4 2025), 2.65% (Q3 2025), and 7.98% (Q2 2025).